Objective: Citalopram has been shown to improve agitation in patients with Alzheimer's disease. The authors evaluated whether other neuropsychiatric symptoms improve with citalopram treatment compared with placebo.
Method: In this planned secondary analysis of the Citalopram for Agitation in Alzheimer's Disease study, the authors evaluated the effect of citalopram on the 12 neuropsychiatric symptom domains assessed by the Neuropsychiatric Inventory (NPI). They compared caregiver-reported NPI scores at week 9 in patients receiving citalopram (30 mg/day) or placebo with regard to both the presence or absence of individual neuropsychiatric symptoms and individual domain scores (reflecting severity) in participants who had symptoms at week 9.
Results: At week 9, participants treated with citalopram were significantly less likely to be reported as showing delusions (odds ratio=0.40), anxiety (odds ratio=0.43), and irritability/lability (odds ratio=0.38). A comparison of median scores of participants with symptoms present at week 9 showed significant differences favoring citalopram for hallucinations and favoring placebo for sleep/nighttime behavior disorders.
Conclusions: While dosage constraints must be considered because of citalopram's adverse effect profile, this agent's overall therapeutic effects in patients with Alzheimer's disease and agitation, in addition to efficacy for agitation/aggression, included reductions in the frequency of irritability, anxiety, and delusions; among patients who had these symptoms at week 9, they included a reduction in the severity of hallucinations but an increase in the severity of sleep/nighttime behavior disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.2016.15020248 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of music-based intervention for people living with dementia in an inpatient setting: A pilot study.
J Alzheimers Dis
January 2025
Department of Psychology and Visual Sciences, University of Leicester, Leicester, UK.
Background: Pharmacological treatment of behavioral and psychological symptoms of dementia is of limited benefit. The addition of non-pharmacological interventions is often essential for optimal symptom control. Music is a viable way to help patients communicate and improve their quality of life.
View Article and Find Full Text PDFInforming etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217.
J Prev Alzheimers Dis
January 2025
1Florida Alzheimer's Disease Research Center, Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA.
Background: Mild cognitive impairment (MCI) is a clinical diagnosis representing early symptom changes with preserved functional independence. There are multiple potential etiologies of MCI. While often presumed to be related to Alzheimer's disease (AD), other neurodegenerative and non-neurodegenerative causes are common.
View Article and Find Full Text PDFDigital screening tool for the assessment of cognitive impairment in unsupervised setting-digiDEM-SCREEN: study protocol for a validation study.
BMJ Open
January 2025
Interdisciplinary Center for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Introduction: Dementia is one of the most relevant widespread diseases, with a prevalence of currently 55 million people with dementia worldwide. However, about 60-75% of people with dementia have not yet received a formal diagnosis. Asymptomatic screening of cognitive impairments using neuropsychiatric tests has been proven to efficiently enhance diagnosis rates.
View Article and Find Full Text PDFSocial functioning and frontal alpha asymmetry in schizophrenia.
J Psychiatr Res
January 2025
Department of Psychological Sciences, University of Connecticut, 406 Babbidge Road, Unit 1020, Storrs, CT, USA.
Background: Schizophrenia (SZ) is a psychiatric disorder that often involves reduced social functioning. Frontal alpha asymmetry (FAA) is a neurophysiological marker extracted from electroencephalogram (EEG) data that is likely related to motivational and emotional tendencies, such as reduced motivation across various psychiatric disorders, including SZ. Therefore, it may offer a neurophysiological marker for social functioning.
View Article and Find Full Text PDFThe association among individual gray matter volume of frontal-limbic circuitry, fatigue susceptibility, and comorbid neuropsychiatric symptoms following COVID-19.
Neuroimage
January 2025
Department of Medical Imaging, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China. Electronic address:
Article Synopsis
- The study investigates the neurobiological factors that make individuals susceptible to fatigue after a mild COVID-19 infection, aiming to understand the link between brain structure and post-COVID neuropsychiatric symptoms.
- Researchers used neuropsychiatric assessments and MRI scans on individuals who had COVID-19 and a control group to analyze brain regions related to fatigue.
- Results indicate that specific brain areas, particularly the right dorsolateral prefrontal cortex, are linked to fatigue severity and can predict ongoing fatigue symptoms months after the infection, shedding light on the neural underpinnings of post-COVID conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!